Updated:
BioRestorative Therapies
BioRestorative Therapies, led by CEO Lance Alstodt, develops allogeneic stem cell therapies for disc and metabolic disorders.
BioRestorative Therapies
#degenerativediscdisease | BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs, as described below, relate to the treatment of disc/spine disease and metabolic disorders:
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Melville
Corporate office
Melville, NY, United States
Principals
Lance Alstodt
Chairman, President and Chief Executive Officer
Sector focus
Frequently asked questions
Is BioRestorative Therapies a family office or an investment fund?
It is neither. BioRestorative Therapies is an operating company — a clinical-stage biotechnology firm publicly listed on NASDAQ. It does not manage external capital, deploy into venture funds, or operate a family patrimony. Its cash is used for internal research, clinical trials, and regulatory work.
What does the company's lead product candidate target?
The lead candidate, BRTX-100, targets chronic lumbar disc disease. It is an autologous cell therapy where a patient's own bone marrow is harvested, cultured, and reinjected to repair damaged discs. The program is in clinical development under FDA oversight.
How does BioRestorative Therapies fund its operations?
It funds operations through periodic capital raises on public markets, typically equity or warrant-linked financings. Being pre-revenue, the company does not generate cash flow from product sales and relies on investor-funded research budgets until a potential FDA approval or partnership.
What is the ThermoStem platform?
ThermoStem is the firm's early-stage metabolic program. It uses stem cells to generate brown adipose tissue, which burns energy rather than storing it. The concept is to develop an allogeneic treatment for obesity and Type 2 diabetes by increasing the body's thermogenic cell count.
Who runs investment decisions at BioRestorative Therapies?
There are no investment decisions in the traditional asset-management sense. Lance Alstodt, as Chairman and CEO, sets corporate strategy and allocates operating capital toward clinical milestones. The firm is not an allocator; it is a biotech developer.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: